Chi-Jung Huang1, Chern-En Chiang2, Bryan Williams3, Kazuomi Kario4, Shih-Hsien Sung5,6, Chen-Huan Chen6,7,8, Tzung-Dau Wang9, Hao-Min Cheng1,6,7,8. 1. Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 2. General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan. 3. Institute of Cardiovascular Sciences, University College London (UCL) and National Institute for Health Research (NIHR) UCL Hospitals Biomedical Research Centre, London, UK. 4. Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan. 5. Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 6. Department of Medicine, National Yang-Ming University, Taipei, Taiwan. 7. Division of Faculty Development, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan. 8. Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan. 9. Division of Cardiology, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: The influence of age on balance of benefit vs. potential harm of blood pressure (BP)-lowering therapy for elderly hypertensives is unclear. We evaluated the modifying effects of age on BP lowering for various adverse outcomes in hypertensive patients older than 60 years without specified comorbidities. METHODS: All relevant randomized controlled trials (RCTs) were systematically identified. Coronary heart disease, stroke, heart failure (HF), cardiovascular death, major adverse cardiovascular events (MACE), renal failure (RF), and all-cause death were assessed. Meta-regression analysis was used to explore the relationship between achieved systolic BP (SBP) and the risk of adverse events. Random-effects meta-analysis was used to pool the estimates. RESULTS: Our study included 18 RCTs (n = 53,993). Meta-regression analysis showed a lower achieved SBP related with a lower risk of stroke and cardiovascular death, but an increased risk of RF. The regression slopes were comparable between populations stratifying by age 75 years. In subgroup analysis, the relative risks of a more aggressive BP lowering strategy were similar between patients aged older or less than 75 years for all outcomes except for RF (P for interaction = 0.02). Compared to treatment with final achieved SBP 140-150 mm Hg, a lower achieved SBP (<140 mm Hg) was significantly associated with decreased risk of stroke (relative risk = 0.68; 95% confidence interval = 0.55-0.85), HF (0.77; 0.60-0.99), cardiovascular death (0.68; 0.52-0.89), and MACE (0.83; 0.69-0.99). CONCLUSIONS: To treat hypertension in the elderly, age had trivial effect modification on most outcomes, except for renal failure. Close monitoring of renal function may be warranted in the management of elderly hypertension.
BACKGROUND: The influence of age on balance of benefit vs. potential harm of blood pressure (BP)-lowering therapy for elderly hypertensives is unclear. We evaluated the modifying effects of age on BP lowering for various adverse outcomes in hypertensive patients older than 60 years without specified comorbidities. METHODS: All relevant randomized controlled trials (RCTs) were systematically identified. Coronary heart disease, stroke, heart failure (HF), cardiovascular death, major adverse cardiovascular events (MACE), renal failure (RF), and all-cause death were assessed. Meta-regression analysis was used to explore the relationship between achieved systolic BP (SBP) and the risk of adverse events. Random-effects meta-analysis was used to pool the estimates. RESULTS: Our study included 18 RCTs (n = 53,993). Meta-regression analysis showed a lower achieved SBP related with a lower risk of stroke and cardiovascular death, but an increased risk of RF. The regression slopes were comparable between populations stratifying by age 75 years. In subgroup analysis, the relative risks of a more aggressive BP lowering strategy were similar between patients aged older or less than 75 years for all outcomes except for RF (P for interaction = 0.02). Compared to treatment with final achieved SBP 140-150 mm Hg, a lower achieved SBP (<140 mm Hg) was significantly associated with decreased risk of stroke (relative risk = 0.68; 95% confidence interval = 0.55-0.85), HF (0.77; 0.60-0.99), cardiovascular death (0.68; 0.52-0.89), and MACE (0.83; 0.69-0.99). CONCLUSIONS: To treat hypertension in the elderly, age had trivial effect modification on most outcomes, except for renal failure. Close monitoring of renal function may be warranted in the management of elderly hypertension.
Authors: H M Perry; W M Smith; R H McDonald; D Black; J A Cutler; C D Furberg; M R Greenlick; L H Kuller; H W Schnaper; J A Schoenberger Journal: Stroke Date: 1989-01 Impact factor: 7.914
Authors: Peter Trenkwalder; Dag Elmfeldt; Albert Hofman; Hans Lithell; Bertil Olofsson; Vasilios Papademetriou; Ingmar Skoog; Alberto Zanchetti Journal: Blood Press Date: 2005 Impact factor: 2.835
Authors: A Amery; W Birkenhäger; P Brixko; C Bulpitt; D Clement; M Deruyttere; A De Schaepdryver; C Dollery; R Fagard; F Forette Journal: Lancet Date: 1985-06-15 Impact factor: 79.321
Authors: Jeff D Williamson; Mark A Supiano; William B Applegate; Dan R Berlowitz; Ruth C Campbell; Glenn M Chertow; Larry J Fine; William E Haley; Amret T Hawfield; Joachim H Ix; Dalane W Kitzman; John B Kostis; Marie A Krousel-Wood; Lenore J Launer; Suzanne Oparil; Carlos J Rodriguez; Christianne L Roumie; Ronald I Shorr; Kaycee M Sink; Virginia G Wadley; Paul K Whelton; Jeffrey Whittle; Nancy F Woolard; Jackson T Wright; Nicholas M Pajewski Journal: JAMA Date: 2016-06-28 Impact factor: 56.272